Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 65CNS 32Genitourinary 20Lymphoid 19Gastrointestinal 19Myeloid 12Dermatologic 6Gynecologic 4Other hematologic neoplasm 3Endocrine 3Plasma cell 2Other solid neoplasm 2Thoracic 1Head & Neck 1Breast 1

Conditions

Head and Neck Neoplasms 408Squamous Cell Carcinoma of Head and Neck 326Thyroid Neoplasms 104Carcinoma, Non-Small-Cell Lung 85Neoplasms 66Oropharyngeal Neoplasms 59Carcinoma, Squamous Cell 59Melanoma 56Lung Neoplasms 47Neoplasm Metastasis 44Mouth Neoplasms 43Breast Neoplasms 42Laryngeal Neoplasms 39Thyroid Cancer, Papillary 36Salivary Gland Neoplasms 35Colorectal Neoplasms 35Ovarian Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Stomach Neoplasms 30Tongue Neoplasms 28Nasopharyngeal Neoplasms 28Uterine Cervical Neoplasms 27Carcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 24Sarcoma 24Carcinoma, Medullary 24Recurrence 22

Interventions

tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma × Head & Neck × Clear all
NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡